The Predictive Value of Circulating Apoptotic Endothelial Cell-Derived Micro Particles in Obesity Progression?

Alexander E. Berezin

Consultant of Therapeutic Unit, Private Medical Center “Vita-Center”, Sedova str, 3, Zaporozhye, 69000, Ukraine

&

Consultant of Therapeutic Unit, Internal Medicine Department, State Medical University of 26, Mayakovskiy av., Zaporozhye, 69035, Ukraine

Copyright © 2017 Alexander E. Berezin. This article is distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Obesity is considered a main factor contributing in diabetes mellitus development and a predictor of CV disease and events. Based on the Adult Treatment Panel-III criteria subjects with established obesity and co-existing other metabolic abnormalities including dyslipidemia, insulin resistance (IR), increased fasting glucose and impaired glucose tolerance, are referred metabolically unhealthy obesity (Met-UHO), whereas obese individuals without these abnormalities might be defined as metabolically healthy obesity (Met-HO). The mechanisms underlying the change in phenotype from metabolically healthy to metabolically unhealthy obesity are still unclear. It has been postulated that apoptotic endothelial cell-derived micro particles (EMPs) might be a trigger of endothelial cell dysfunction and as well as a mediator on vascular repair. Moreover, the imbalance in circulating number of various type of EMPs may influence the risk of transformation of Met-HO into Met-UHO. The short communication is depicted the role of apoptotic EMPs in obesity phenotype modification.

Keywords: Metabolically healthy obesity; metabolically unhealthy obesity; endothelial cell-derived micro particles; insulin resistance
Introduction

The prevalence of abdominal obesity has been raised worldwide achieving epidemic level [1]. Recent observation and clinical studies have clearly established that abdominal obesity especially morbid obesity (body mass index [BMI] more than 40 kg/m\(^2\)) related strongly to all cause and cardiovascular (CV) morbidity and mortality, as well as closely associated with a risk of type 2 diabetes mellitus (T2DM) [2]. However, there is evidence regarding progressive annually increase of prediabetes / T2DM prevalence irrespectively BMI [3, 4]. Additionally, obese individuals with similar BMI may be protected or opposite predisposed to obesity-related complications (i.e. T2DM, dyslipidemia, hypertension) and CV disease [5]. The speculations around so called a protective role of obesity in CV disease leaded to appearance of a term “obesity paradox”, which is referred as shaping U-curve between BMI and CV mortality [6]. It is suggested that “obesity paradox” might be a mismatch between different definitions of obesity in particularly based on BMI measurement. Therefore, the heterogeneity of obesity induced the concept of emerging metabolic phenotypes associated with obesity e.g. metabolically unhealthy obesity (Met-UHO) and metabolically healthy obesity (Met-HO) distinguished from each other for CV risk [7]. Based on the Adult Treatment Panel-III criteria subjects with established obesity and co-existing other metabolic abnormalities including dyslipidemia, insulin resistance (IR), increased fasting glucose and impaired glucose tolerance, are referred Met-UHO, whereas obese individuals without these abnormalities might be defined as Met-HO [8]. The mechanisms underlying the change in phenotype from metabolically healthy to metabolically unhealthy obesity are still unclear. Whether Met-HO is an early stage and transient state in the pathway to Met-UHO and T2DM is not understood.

Micro particles (MPs) are defined a heterogeneous sub-population of extracellular vesicles with diameter average from 100 to1000 nm originated from plasma membranes of mother’ cells [9]. As a derivate of cellular membrane MPs are discussed powerful paracrine regulators of target cell structure and functions. MP released by apoptotic endothelial cells posse a wide spectrum of biological effects on intercellular communication by transferring different active molecules (proteins, peptides, hormones, growth factors, microRNAs) exhibiting coagulation activity, mediating cell growth and tissue differentiation [10]. Additionally, apoptotic endothelial cell-derived MPs (EMPs) may directly worsen endothelial integrity and vascular function playing a pivotal role in development of microvascular inflammation and IR [11].

Recent clinical studies have shown that the circulating levels of apoptotic EMPs were significantly increased in T2DM patients as compared with healthy volunteers [12] and they mediated CV risk in patients with established metabolic syndrome (MetS) and T2DM [13-15]. Probably apoptotic EMPs may involve in the transformation of Met-HO into Met-UHO determining the risk of T2DM and CV disease. Indeed, the increased number of CD31\(^+\)/ Annexin V\(^+\) and CD144\(^+\)/ Annexin V\(^+\) EMPs much more more pretty accurate predicted Met-UHO and closely
Endothelial cell-derived micro particles in obesity

associated with IR [16]. Thus, the most important factor that affects metabolic dysregulation in obesity is IR, which probably appears to be predominantly early stage of the Met-HO.

There is evidence that an accumulation of visceral adiposity tissue (VAT) might associate with over-production of pro-inflammatory cytokines including hs-CRP, leptin and vistafin and induce IR [17]. Therefore, infiltration of the sub-intima by LDL cholesterol may induce production of free radicals, oxidation of cytoskeleton and membrane vesiculation of endothelial cells. Finally, membrane vesiculation of endothelial cells is enhanced by inflammatory cytokines in conveying of VAT accumulation.

Interestingly, the circulating number of apoptotic EMPs has well associated with conventionally obesity biomarkers (adiponectin, leptin, vistafin) in Met-UHO patients, but did not in Met-HO individuals. Indeed, in Met-HO patients we did not find severe metabolic abnormalities apart from leptin elevation compared with Met-UHO, however, IR was determined as common finding for both Met-UHO and Met-HO individuals without a difference in BMI.

The increased amount of VAT together with a chronic inflammation and IR predisposes to the development of endothelial dysfunction through attenuation synthesis and secretion of apoptotic EMPs. Indeed, pro-inflammatory cytokines, i.e. interleukin-6, tumor factor necrosis-alpha, leptin, and vistafin, may directly influence structure of endothelial cells and trigger a secretion of apoptotic EMPs [18-20]. The main biological function of this process is an attenuation of endothelial cell repair and recovery of vascular function [21]. Unfortunately, co-existing IR affects endothelial progenitor cells and they are not able to differentiate into functionally mature endothelial cells even after stimulation by apoptotic EMPs [22]. As a result, apoptotic EMP-induced endothelial dysfunction and IR may become an early predictor of shaping Met-UHO.

Recently it has reported that apoptotic EMPs may independent predict asymptomatic atherosclerosis and CV disease in T2DM patients [23], while their role in individuals with different phenotypes of obesity has remained controversial. First, it is not clear whether increased number of apoptotic EMPs is adaptive mechanism of vascular repair or factor of endothelial injury. Indeed, circulating EPMs, which are enhanced in a large number of metabolic disorders including abdominal obesity, associated with IR and this has been linked to deleterious effects on endothelial cells [24, 25]. At the same time, apoptotic EPMs are powerful factor contributing in endothelial progenitor cell mobbing and differentiation. Secondary, it is not fully understand the innate molecular mechanisms, which correspond to triggers of secretion of these apoptotic MPs.

Apoptotic MPs as cargo microvesicles consist of a variety of biomolecules including regulated proteins, DNA, mRNA, and non-coding RNA [23]. The proportion of these components as well as an entire secretome is under a tight control of autocrine / paracrine mechanisms and inflammatory factors (i.e. tumor necrosis factor-alpha, interleukin-2, -6), which induces EMP formation in a time-dependent manner [9, 10, 25]. Consequently, the final reply of the recipient cells, such as endothelial progenitor cells, is depends on epigenetic regulation of secretome
secretion and primary trigger, which affects vesiculation [10]. Obviously, an ability of apoptotic EMPs to modulate immune and inflammatory processes, coagulation and vascular function, angiogenesis and vascular injury may interact with other regulatory mechanisms the role of which in the pathogenesis of abdominal obesity requires still being determined. It is no excluded that release of apoptotic EMPs might act as a direct endogenous survival signal for target cells.

In conclusion, measurement of circulating apoptotic EMP number would be useful tool for stratification amongst obesity individuals at higher risk of T2DM and CV, especially when conventional biomarkers of obesity are not detected in appropriate diagnostic level. Large investigations are required to understand the role of apoptotic EMPs in pathogenesis of different phenotypes of abdominal obesity, because they may be a target of the therapy as well as predictive biomarkers.

**Funding and grants:** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflicts of interest:** none.

**References**


diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD), *European Heart Journal*, 34 (2013), 3035-3087. https://doi.org/10.1093/eurheartj/eht108


https://doi.org/10.1007/s00395-011-0198-4

Immune phenotypes of endothelial-derived microparticles in dysmetabolic 
https://doi.org/10.4172/jpb.1000353

[25] A. Berezin, Cardiac biomarkers in diabetes mellitus: new dawn for risk 
stratification?, *Diabetes & Metabolic Syndrome: Clinical Research & 
[epub ahead of print]

Received: February 1, 2017; Published: February 9, 2017